• Citer

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.

par Majewski, Ian IJ;Nuciforo, Paolo;Mittempergher, Lorenza;Bosma, Astrid AJ;Eidtmann, Holger;Holmes, Eileen;Sotiriou, Christos ;Fumagalli, Debora ;Jimenez, Jose;Aura, Claudia;Prudkin, Ljudmila;Díaz-Delgado, Maria Carmen;de la Peña, Lorena;Loi, Sherene ;Ellis, Catherine;Schultz, Nikolaus;de Azambuja, Evandro ;Harbeck, Nadia;Piccart-Gebhart, Martine ;Bernards, René;Baselga, José
Référence Journal of clinical oncology
Publication Publié, 2015-01

Article révisé par les pairs

• Détails
• Contenu

Titre:	PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.
Auteur:	Majewski, Ian IJ; Nuciforo, Paolo; Mittempergher, Lorenza; Bosma, Astrid AJ; Eidtmann, Holger; Holmes, Eileen; Sotiriou, Christos; Fumagalli, Debora; Jimenez, Jose; Aura, Claudia; Prudkin, Ljudmila; Díaz-Delgado, Maria Carmen; de la Peña, Lorena; Loi, Sherene; Ellis, Catherine; Schultz, Nikolaus; de Azambuja, Evandro; Harbeck, Nadia; Piccart-Gebhart, Martine; Bernards, René; Baselga, José
Informations sur la publication:	Journal of clinical oncology
Statut de publication:	Publié, 2015-01
Sujet CREF:	Cancérologie
	Médecine pathologie humaine
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2014.55.2158
	info:pii/JCO.2014.55.2158
	info:scp/84927620697
	info:pmid/25559818